Cambridge Healthtech Institute’s 4th Annual

Oncolytic Virus Immunotherapy

Realizing the Exciting Potential of Oncolytic Virotherapy

August 6-7, 2019



Oncolytic virotherapy (OV) represents an exciting new area of cancer treatment by exploiting a virus’s ability to selectively replicate and kill tumor tissue while stimulating a patient-specific immune response against cancer. Interest in the field is at an all-time high following significant scientific breakthroughs in mechanisms of action, efficacy, combination therapies, delivery, and investment from big pharma players such as Pfizer, Amgen, Merck, Johnson and Johnson.

CHI’s Oncolytic Virus Immunotherapy conference brings together leading industry and academic leaders to discuss the critical steps needed to accelerate oncolytic virus immunotherapy, from delivery to combination therapy strategies; virus engineering to manufacturing and commercialization.

LATEST DEVELOPMENTS IN ONCOLYTIC VIROTHERAPY

Latest Updates and Future Directions in Oncolytic Virus Immunotherapy
Joseph C. Glorioso, PhD, Professor, Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine

ONCOLYTICS IN AN ERA OF COMBINATION THERAPIES

Oncolytics in an Era of Combination Therapies
Howard Kaufman, PhD, CMO, Replimmune

Combinatorial Treatment with Oncolytic Adenoimmunotherapy and CAR T-Cell Therapy for Solid Tumor Treatment Masataka Suzuki, PhD, Assistant Professor, Center for Cell & Gene Therapy, Dept. of Medicine, Baylor College of Medicine

Next Generation OV and New Combinational Approaches for Treatment of Solid Tumors
Paola Grandi, PhD, CSO, Cold Genesys

IMPROVING OV POTENCY, TARGETING AND EFFICACY

T-SIGn Virus Approach to Cancer Gene Therapy – Driving the Tumor Cells to Express Combinations of Biological Therapeutics within the Tumor Microenvironment
Brian Champion, PhD, CSO, Psioxus Therapeutics

Arming OVs to Improve Potency, Targeting and Efficacy
Christophe Queva, PhD, CSO, Oncorus

Update from IGNITE Immunotherapy
David Kirn, MD, Co-Founder & Executive Chairman, IGNITE Immunotherapy

Systemic OV Therapy Using Voyager-V1
Stephen J. Russell, MD, PhD, CEO, Vyriad, Inc.

Creating an Immunotherapeutic Battleship to Overcome Tumor Heterogeneity
John Bell, PhD, Senior Scientist, Center for Innovative Cancer Research, Ottawa Hospital Research Institute


For more details on the conference, please contact:

Daniel Barry
Senior Conference Director
Cambridge Healthtech Institute
Phone: (+1) 781-247-6266
Email: dbarry@healthtech.com

For partnering and sponsorship information, please contact:
Rod Eymael
Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-247-6286
Email: reymael@healthtech.com



Connect With Us

MEETING SUGGESTIONS

For meeting questions or suggestions, please contact:

Julia Boguslavsky
Executive Director, Conferences
Cambridge Healthtech Institute
juliab@healthtech.com

PARTNERING & SPONSORSHIP

For partnering and sponsorship info, please contact:

Rod Eymael
Manager, Business Development
Cambridge Healthtech Institute
+1 781.247.6286
reymael@healthtech.com

MEDIA & ASSOCIATION

For media and association partnerships, please contact:

Pete DeOlympio
Sr. Marketing Manager
Cambridge Healthtech Institute
+1 781.972.5415
peted@healthtech.com